Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
Data(s) |
01/10/2004
|
---|---|
Identificador |
http://dx.doi.org/10.1007/s11102-005-1756-2 http://www.scopus.com/inward/record.url?scp=33644670829&partnerID=8YFLogxK |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
Lindsay , J 2004 , ' Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. ' Pituitary , vol 7(3) , no. 3 , pp. 139-144 . DOI: 10.1007/s11102-005-1756-2 |
Palavras-Chave | #/dk/atira/pure/subjectarea/asjc/1300/1310 #Endocrinology |
Tipo |
article |